Ambu A/ S stock (DK0060946788): CEO speaks at MedTech Forum 2026

Ambu A/S CEO Britt Meelby Jensen is scheduled to speak at The MedTech Forum on May 13, 2026, highlighting the company's role in medical technology innovation amid its OMXC25 index inclusion.

Ambu A/S, a Danish medtech firm focused on single-use endoscopy devices, gains visibility as CEO Britt Meelby Jensen is set to present at The MedTech Forum 2026 on May 13, according to The MedTech Forum as of 05/14/2026. The event features discussions on fostering medical technology advancements. Ambu remains a constituent of the OMXC25 index on Nasdaq Copenhagen, with data current as of May 8, 2026, per Nasdaq OMX as of 05/08/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Ambu A/S
• Sector/industry: Medical devices (endoscopy)
• Headquarters/country: Denmark
• Core markets: Europe, US, Asia
• Key revenue drivers: Single-use endoscopes, visualization systems
• Home exchange/listing venue: Nasdaq Copenhagen (AMBU B)
• Trading currency: DKK

Ambu A/S: core business model

Ambu A/S develops and manufactures single-use medical devices, primarily flexible endoscopes used in endoscopy procedures. The company emphasizes infection prevention through disposable products, reducing cross-contamination risks in hospitals. This model positions Ambu in the growing medtech segment focused on patient safety and procedural efficiency.

Headquartered in Ballerup, Denmark, Ambu operates globally with manufacturing in Asia and sales in over 100 countries. Its portfolio includes endoscopy solutions for gastrointestinal, pulmonary, and urology applications, alongside advanced visualization systems. For US investors, Ambu's products are relevant in American hospitals adopting single-use tech to meet hygiene standards post-COVID.

Main revenue and product drivers for Ambu A/S

Revenue primarily stems from single-use flexible endoscopes, which accounted for the bulk of sales in recent periods. Key products like the aScope line dominate, offering on-demand endoscopy without reprocessing needs. Growth is driven by procedural volume increases in emerging markets and US adoption, where single-use devices address regulatory scrutiny on reusable scopes.

Ambu reported expansions in its visualization systems, integrating AI for better procedural outcomes. The company's focus on R&D supports pipeline development, targeting cardiology and neurology applications. US market exposure provides tailwinds from healthcare spending, making it noteworthy for American portfolios tracking medtech innovation.

Industry trends and competitive position

The medtech sector sees rising demand for single-use devices amid infection control priorities. Ambu competes with giants like Boston Scientific and Olympus but leads in disposable endoscopy niches. Its OMXC25 inclusion signals market recognition, with weighting data from Nasdaq OMX as of 05/08/2026.

Why Ambu A/S matters for US investors

Ambu's US revenue share exposes it to American healthcare dynamics, including Medicare reimbursements for advanced endoscopy. Listed on Nasdaq Copenhagen, shares are accessible via US brokers, offering diversification into European medtech with US growth levers. Events like CEO appearances at global forums underscore strategic outreach relevant to cross-Atlantic investors.

Conclusion

Ambu A/S continues to advance in single-use medtech, with CEO Jensen's MedTech Forum appearance on May 13 highlighting innovation efforts. OMXC25 status reflects stability, while US market ties offer exposure to procedural growth. Investors track such developments alongside sector trends for context.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.